Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer
| Autor: | Tadashi Igishi, Masahiro Kodani, Tomohiro Sakamoto, Kenichi Takeda, Hirokazu Touge, Eiji Shimizu, Hiroki Izumi, Yasuto Ueda, Shizuka Nishii-Ito, Akira Yamasaki, Natsumi Tanaka, Haruhiko Makino, Kosuke Yamaguchi, Masaaki Yanai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology Adult Male Cancer Research medicine.medical_specialty animal structures Lung Neoplasms T cell T-Lymphocytes Cell Count Lymphocyte Activation Zoledronic Acid 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Medicine Humans 030212 general & internal medicine Epidermal growth factor receptor Lung cancer Acute-Phase Reaction Aged Retrospective Studies Aged 80 and over biology business.industry Acute-phase protein Cancer Retrospective cohort study Receptors Antigen T-Cell gamma-delta Middle Aged medicine.disease Prognosis Survival Analysis medicine.anatomical_structure 030220 oncology & carcinogenesis biology.protein Tumor necrosis factor alpha Female Non small cell business Follow-Up Studies |
| Zdroj: | Lung cancer (Amsterdam, Netherlands). 122 |
| ISSN: | 1872-8332 |
| Popis: | Objectives Zoledronate (ZOL) is usually used for prevention of skeletal-related events in cancer patients with bone metastases. The first administration of ZOL is occasionally associated with development of acute-phase reaction (APR), which is due to activation of γδ T cells. ZOL-related APR was associated with better overall survival (OS) of patients with non-small cell lung cancer (NSCLC) in our previous retrospective study. However, it remains to be clarified whether γδ T cells are more activated in patients who experienced ZOL-related APR, and whether γδ T cell activation is involved in prolongation of OS. Materials and Methods Twenty-three patients with advanced NSCLC were recruited between 2012 and 2014 in this study. We administered ZOL to participants with standard care. The patient characteristics, change in γδ T cell counts and cytokines, OS, and skeletal-related event-free survival were compared between patients with APR (APR group) and those without APR (non-APR group). Results Ten patients (43.5%) experienced a ZOL-related APR. The number of γδ T cells at baseline in the APR group was significantly higher than that in the non-APR group. Serum interleukin-6 and tumor necrosis factor-α in the APR group were significantly increased, but no change in the number of γδ T cells was observed after the first administration of ZOL in both groups. OS in the APR group was significantly longer than that in the non-APR group (median survival time: 23.1 vs. 14.5 months, p Conclusion We showed that APR is related to higher numbers of γδ T cells at baseline and increased cytokines after the first ZOL administration, but not to proliferative responses of γδ T cells. In addition, better OS was observed in the APR group. Therefore, the number of γδ T cells might be a prognostic marker in patients with NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect